Epigral Ltd Q2 FY26 – From Chlor-Alkali to Chemistry of Confidence (₹587 Cr Revenue, ₹51 Cr PAT, and a Boardroom Twist)
1. At a Glance
Epigral Limited (NSE: EPIGRAL, BSE: 543332), formerly known as Meghmani Finechem, is currently mixing not just chemicals but a potent cocktail of expansion, capex, and confidence. With a market cap of ₹6,424 crore and a stock price of ₹1,489 (down nearly 18% over the last quarter), the company is churning reactions that make even organic chemistry feel simple.
In Q2 FY26, the company clocked ₹587 crore in revenue (down 6.18% QoQ) and a PAT of ₹51.5 crore (down 36% QoQ). For the first half of FY26, revenue stood at ₹1,204 crore, showing steady performance despite industry headwinds. Operating margins are holding the line at a respectable 23%, even as realizations across its Chlor-Alkali and derivative segments continue to normalize from their pandemic highs.
Meanwhile, the company’s CFO has resigned (Sanjay Jain), and a new one, Rakesh Agrawal, has joined just as Epigral’s ₹780 crore expansion plan is stirring the pot. The boardroom’s reaction seems as dynamic as its chemical reactors.
2. Introduction
Once upon a time, Meghmani Finechem was a humble caustic soda manufacturer. Fast forward to today, and Epigral Limited has evolved into a specialty chemical powerhouse operating at the intersection of molecules, margins, and madness. From Chloromethanes to Epichlorohydrin (try saying that five times fast), Epigral is synthesizing not just chemicals, but also scale.
Its Dahej complex, spread across 60 hectares, runs like a chemical orchestra — backward and forward integrated, automated, and unapologetically Gujarati in its efficiency. While some chemical companies love calling themselves “green,” Epigral actually put money where its mouth is — investing ₹21.38 crore for a 26% stake in a 19.8 MW renewable power SPV. Clean energy meets chlorinated ambition.
FY25 wasn’t an easy year for the chemical sector, but Epigral still managed to grow revenue by 33%, PAT by 82%, and win a CRISIL rating upgrade to AA/Stable. For FY26, the company has set itself a clear roadmap — expand CPVC and Epichlorohydrin capacities, launch new Chlorotoluenes facilities, and push specialty products to form 70% of its revenue by FY27.
But as every chemist knows, too much reaction leads to explosion — and investors are wondering whether Epigral’s aggressive capex cycle (₹1,000+ crore till FY27) will yield clean profits or a chemical hangover.
3. Business Model – WTF Do They Even Do?
Epigral is basically the “Breaking Bad” of Indian specialty chemicals, minus the illegal part. The company’s operations can be distilled (pun intended) into two big beakers:
a) Derivatives & Specialty Chemicals (56% of H1 FY25 revenue): This segment includes high-value products like CPVC resin, Epichlorohydrin, Hydrogen Peroxide, and the Chlorotoluenes Value Chain. Epigral is India’s first company to set up an Epichlorohydrin plant — a key raw material for epoxy resins and coatings — and also boasts India’s largest CPVC resin capacity at 75 KTPA.
b) Chlor-Alkali (44% of H1 FY25 revenue): Think of this as the “OG” business — producing Caustic Soda, Caustic Potash, Chlorine, and Hydrogen. It’s steady, cash-generating, and not particularly sexy, but necessary.
The company’s growth playbook is simple: → Use cash from Chlor-Alkali to fund Specialty Chemicals. → Build scale, then backward integrate. → Use automation to squeeze costs. → Finally, diversify into downstream derivatives that bring higher margins and customer stickiness.
Clients include heavyweights like Cardolite, Supreme Industries, Astral Pipes, Atul, Vedanta, SRF, IPCA Labs, and Divi’s — not a bad list to flex.
Commentary: When your quarterly profit drops 68% QoQ, you either panic or make memes. Epigral is doing the latter, because FY26 is all about capex digestion. EBITDA margins fell from 27% to 23%, largely due to subdued realizations in Chloromethanes and hydrogen peroxide. But hey, at least revenue didn’t implode — that’s a win in chemicals.
5. Valuation Discussion – Fair Value Range
Method 1: P/E Approach
FY25 EPS = ₹93.2
Industry average P/E = 30.7× (from screener)
Fair value range = ₹93.2 × (18× – 25×) = ₹1,678 – ₹2,330
